

## MMK1

<b>Cat. No.:</b>	HY-P1117
<b>CAS No.:</b>	271246-66-3
<b>Molecular Formula:</b>	C <sub>75</sub> H <sub>123</sub> N <sub>19</sub> O <sub>18</sub> S
<b>Molecular Weight:</b>	1610.96
<b>Sequence:</b>	Leu-Glu-Ser-Ile-Phe-Arg-Ser-Leu-Leu-Phe-Arg-Val-Met
<b>Sequence Shortening:</b>	LESIFRSLFRVM
<b>Target:</b>	Formyl Peptide Receptor (FPR); Calcium Channel
<b>Pathway:</b>	GPCR/G Protein; Membrane Transporter/Ion Channel; Neuronal Signaling
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	MMK1 is a potent and selective human formyl peptide receptor like-1 (FPRL-1/FPR2) agonist with EC <sub>50</sub> s of <2 nM and >10000 nM for FPRL-1 and FPR1, respectively. MMK1 is a potent chemotactic and calcium-mobilizing agonist. MMK1 potently activates phagocytic leukocytes and enhances Pertussis Toxin (HY-112779)-sensitive production by human monocytes of proinflammatory cytokines IL-1b and IL-6. MMK1 exerts anxiolytic-like activity <sup>[1][2][3][4]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	Calcium Channel
<b>In Vitro</b>	MMK-1 induces calcium mobilization in human FPRL1-transfected HEK 293 (FPRL1/293) cells with an EC <sub>50</sub> of 2 nM <sup>[1]</sup> . MMK1 (1 μM; for 4 h) induces selective migration of FPR2-expressing RBL-2H3 cells <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	MMK1 (10-1000 pmol; ICV; 20 min before the test) exerts an anxiolytic-like activity at a dose of 100 pmol/mouse <sup>[4]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>Animal Model:</b>	Four-week-old male ddY mice <sup>[4]</sup>
<b>Dosage:</b>	10, 100, 1000 pmol/mouse
<b>Administration:</b>	ICV; 20 min before the test
<b>Result:</b>	Exerted an anxiolytic-like activity at a dose of 100 pmol/mouse.

### REFERENCES

- [1]. C Klein, et al. Identification of surrogate agonists for the human FPRL-1 receptor by autocrine selection in yeast. *Nat Biotechnol.* 1998 Dec;16(13):1334-7.
- [2]. Phuong Doan, et al. Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity. *Cells.* 2021 Aug 3;10(8):1975.
- [3]. Yoo Jung Park, et al. A novel antimicrobial peptide acting via formyl peptide receptor 2 shows therapeutic effects against rheumatoid arthritis. *Sci Rep.* 2018 Oct

---

2;8(1):14664.

[4]. Hui Zhao, et al. Rubimetide, humanin, and MMK1 exert anxiolytic-like activities via the formyl peptide receptor 2 in mice followed by the successive activation of DP1, A2A, and GABAA receptors. Peptides. 2016 Sep;83:16-20.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA